Legason, Ismail D.
Ogwang, Martin D.
Chamba, Clara
Mkwizu, Elifuraha
El Mouden, Claire
Mwinula, Hadija
Chirande, Lulu
Schuh, Anna
Chiwanga, Faraja
Funding for this research was provided by:
National Institute for Health Research (NIHR200133)
Article History
Received: 25 December 2021
Accepted: 17 April 2022
First Online: 2 May 2022
Declarations
:
: This protocol was presented to the institutional review boards (IRB) of each participating institution and IRB approval was obtained from the Oxford Tropical Research Ethics Committee (OxTREC Ref:15–19), National Institute of Medical Research (NIMR Reg No. NIMR/HQ/R.8a/Vol.IX/3408) in Tanzania, Uganda National Council of Science and Technology (UNCST Reg No. HS529ES), and Lacor Hospital Institutional Research Ethics Committee (LHIREC No. 074/05/19) in Uganda.Initial REC approval was given on the 6th February 2019 (protocol V3.1), and the current protocol V3.3 was approved on 4th April 2021 via substantial amendment.Participants are enrolled in the study only after written informed consent or assent has been obtained from the patient as per the IRB guidelines.
: Not applicable.
: AS receives Honoria from Gilead, Abbvie, Roche, Janssen, and Illumina.AS receives unrestricted educational grants from Janssen and Gilead.AS receives in-kind contributions from Illumina and Oxford Nanopore Technologies Ltd.IDL, MDO, CC, EM, CEM, HM, LC, & FC do not have any conflict of interest to declare.